Riskpilot← Back to searchSign inGet full accessCell2Bio AB
ABActiveOrg 5594354895Madängsgatan 12 Lgh 1601Research and experimental development on natural sciences and engineering · NACE 7210Est. 20233 employees
Revenue 2024
SEK 0
EBITDA margin
—
-528% vs 2023
Equity ratio
84.7%
Financial strength
Net profit 2024
SEK -697K
-529% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -696K | -528% |
| Net profit | SEK -697K | -529% |
| Total assets | SEK 609K | -14% |
| Equity | SEK 516K | -22% |
| Employees | 3 | — |
Legal name
Cell2Bio AB
Org number
5594354895
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 maj 2023
Share capital
SEK 28 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Stålemark, Jan Ingvar Georg i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning inom biomedicin och bioteknik för diagnostik ändamål och läkemedelsutveckling samt idka därmed förenlig verksamhet. infrastrukturutveckling och service inklusive konsultarbete för läkemedels- och IT-företag.
Address
Madängsgatan 12 Lgh 1601
Email
jan@healthtechsweden.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | −0 | 0 |
| Staff expenses | — | — |
| EBITDA | −111 | −696 |
| Depreciation & amort. | — | −0 |
| EBIT | −111 | −696 |
| Net financials | — | — |
| Profit before tax | −111 | −697 |
| Tax | — | −0 |
| Net profit | −111 | −697 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 705 | 609 |
| Equity | 663 | 516 |
| Long-term debt | — | 0 |
| Short-term debt | 42 | 92 |
| Total debt | 42 | 92 |
EBITDA margin
-69600000.0%
This company
15.8%
Market median
-440506429% vs market
20232024
Equity ratio
84.7%
This company
38.2%
Market median
+122% vs market
20232024
Return on equity
-135.1%
This company
18.4%
Market median
-834% vs market
20232024
Net profit margin
-69700000.0%
This company
8.1%
Market median
-860493927% vs market
20232024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20232024
Debt / equity
0.18×
This company
0.62×
Market median
+71% vs market
20232024
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JI Chief Executive Officer | Chief Executive Officer | 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cell2Bio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Ingvar Georg Stålemark | Chief Executive Officer | 0 companies |
| Harisha Ramachandraiah | Board of Directors | 0 companies |
| Aman Russom | Chairman | 0 companies |
| Anders Torbjörn Mathias Pettersson | Board of Directors | 0 companies |